SOURCE: NXP Semiconductors

NXP Semiconductors

SmartSponge, SmartWand-DTX

April 04, 2011 08:00 ET

NXP Technology Aids "No Sponge Left Behind" in Surgical Procedures

RFID-Based SmartSponge System Helps Prevent Retained Foreign Objects in Surgical Patients

EINDHOVEN, NETHERLANDS and PITTSBURGH, PA--(Marketwire - April 4, 2011) -   NXP Semiconductors (NASDAQ: NXPI), the RFID leader for multi-applications, announced that ClearCount Medical Solutions has selected NXP RFID solutions to enable its SmartSponge® System. The SmartSponge System can easily and accurately detect and account for surgical sponges placed in a patient's body when undergoing surgery, so that no items are "left behind," thus improving patient safety.

The SmartSponge System is comprised of RFID-enabled surgical sponges; an embedded RFID reader within a user-friendly automated software accounting system; an accompanying SmartWand to detect sponges accidently retained within the body; and a smart disposal system to account for discarded sponges.

David Palmer, CEO of ClearCount, said: "Our SmartWand-DTX and SmartSponge System, the first Food and Drug Administration-cleared RFID-based platform for the operating room, can help save patients from serious complications that can arise when surgical sponges are left behind. Our solutions also provide renewed confidence -- for doctors, hospitals and insurance agencies -- that they are providing the highest level of patient safety."

The incidence of retained foreign objects (RFOs) in surgical patients is difficult to estimate, partly because they can remain in the body undetected for years. A 2008 study published in The Journal of the American College of Surgeons reported that foreign objects were left behind in 1 out of every 5,500 surgical procedures. In abdominal surgeries, retained foreign objects are estimated to occur in one out of every 1,000 to 1,500 surgical procedures.

Surgical sponges are widely reported to be the most common RFO, because they can be difficult to visually detect once they are saturated in blood. A landmark article in The New England Journal of Medicine reported that sponges accounted for 69 percent of the retained foreign objects studied. Further, even when counts of sponges and other surgical instruments had been performed, 88 percent of cases involved a final count that had been falsely thought to be correct. In complex, time-critical operations, especially where multiple surgeons are involved, the possibility of retained foreign surgical devices within the patient is unfortunately a reality, and the results can be life-threatening.

Victor Vega, RFID marketing director, NXP Semiconductors, said: "Surgical sponges could be counted manually or with the assistance of a barcode reader, but neither of these methods is able to identify any blood-soaked sponges that are hidden in the body. NXP's RFID-based system enhances accountability with a unique read before, during and after the surgery, which dramatically improves accuracy as well as patient safety."

Each surgical SmartSponge is uniquely identifiable with a serial number that can be acquired wirelessly, even if accidently left within the body, by waving the SmartWand over the patient. RFID-enabled SmartSponges are packaged in pre-defined quantities. As the package is waved over an RFID reader, the unique serial numbers of the SmartSponges are read and the system ensures a match with the pre-determined package count. A SmartBucket™ configured with an RFID reader enables the ClearCount system to directly account for and reconcile all sponges entering into and exiting the sterile field. As final assurance, the SmartWand is used to scan the patient to ensure no sponges are left inside of the patient.

Further information, a demo and samples of the SmartSponge System will be available at the NXP booth 204 at RFID Journal LIVE! 2011 in Orlando, Florida, April 12 to 14. For a video of the SmartSponge System, visit

About ClearCount Medical Solutions
ClearCount Medical Solutions is a medical device company focused on patient safety solutions. ClearCount has assembled an extendable RFID-based platform that provides a comprehensive solution to improve efficiency while preventing medical errors. ClearCount Medical Solutions has been recognized with a Popular Science 2009 Best of What's New Award, and has received additional recognition from TIME and WIRED magazines, the 2009 Wall Street Journal Technology Innovation Award, the International Design Excellence Award (IDEA) and more. ClearCount's SmartSponge and SmartWand-DTX systems are the first RFID enabled systems for counting and detecting surgical sponges, thereby improving patient and OR safety, enhancing productivity, and reducing cost. To learn more, visit

About NXP Semiconductors
NXP Semiconductors N.V. (NASDAQ: NXPI) provides High Performance Mixed Signal and Standard Product solutions that leverage its leading RF, Analog, Power Management, Interface, Security and Digital Processing expertise. These innovations are used in a wide range of automotive, identification, wireless infrastructure, lighting, industrial, mobile, consumer and computing applications. A global semiconductor company with operations in more than 30 countries, NXP posted revenue of $4.4 billion in 2010. For more information visit

Forward-looking Statements
This document includes forward-looking statements which include statements regarding our business strategy, financial condition, results of operations, and market data, as well as any other statements which are not historical facts. By their nature, forward-looking statements are subject to numerous factors, risks and uncertainties that could cause actual outcomes and results to be materially different from those projected. These factors, risks and uncertainties include the following: market demand and semiconductor industry conditions, our ability to successfully introduce new technologies and products, the demand for the goods into which our products are incorporated, our ability to generate sufficient cash, raise sufficient capital or refinance our debt at or before maturity to meet both our debt service and research and development and capital investment requirements, our ability to accurately estimate demand and match our production capacity accordingly or obtain supplies from third-party producers, our access to production from third-party outsourcing partners, and any events that might affect their business or our relationship with them, our ability to secure adequate and timely supply of equipment and materials from suppliers, our ability to avoid operational problems and product defects and, if such issues were to arise, to correct them quickly, our ability to form strategic partnerships and joint ventures and successfully cooperate with our alliance partners, our ability to win competitive bid selection processes to develop products for use in our customers' equipment and products, our ability to successfully establish a brand identity, our ability to successfully hire and retain key management and senior product architects; and, our ability to maintain good relationships with our suppliers. In addition, this document contains information concerning the semiconductor industry and our business segments generally, which is forward-looking in nature and is based on a variety of assumptions regarding the ways in which the semiconductor industry, our market segments and product areas will develop. We have based these assumptions on information currently available to us, if any one or more of these assumptions turn out to be incorrect, actual market results may differ from those predicted. While we do not know what impact any such differences may have on our business, if there are such differences, our future results of operations and our financial condition could be materially adversely affected. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak to results only as of the date the statements were made. Except for any ongoing obligation to disclose material information as required by the United States federal securities laws, we do not have any intention or obligation to publicly update or revise any forward-looking statements after we distribute this document, whether to reflect any future events or circumstances or otherwise. For a discussion of potential risks and uncertainties, please refer to the risk factors listed in our SEC filings. Copies of our SEC filings are available from on our Investor Relations website, or from the SEC website,